12.03.19
NHS Trusts collaborate with industry to improve cancer patient outcomes
Source: Advertisement commissioned and paid for by Novartis Pharmaceuticals UK Ltd.
Novartis Oncology has worked with the NHS on 55 JWPs since 2014, focusing on areas including improving the patient experience, redesigning cancer services, harnessing service data, and piloting innovative care models.
JWPs can lead to rapid, significant gains in improving the patient experience, while helping the wider Health Service become more efficient and productive. JWPs are “tried and tested” in real-world settings, meaning they can be easily implemented by hospitals experiencing similar challenges.
JWPs should be viewed as an enabler for delivering NHS cancer strategies in each UK nation and will continue to play a valuable role in health service development. Those undertaken by Novartis Oncology show how relatively small changes can lead to rapid, significant gains in improving patient experience and contribute to designing a more efficient and productive NHS. Learnings from JWPs in individual Trusts can be shared and implemented elsewhere.
Novartis Oncology wants to continue to work with Trust partners to identify collaborative projects that will benefit people living with cancer in the UK.
To find out more about Novartis’ commitment to working in collaboration with the NHS, download our report, Working Together to improve Cancer Outcomes. The results can be compelling, as the case studies in the report explain.
Case study: Increasing capacity while improving patient experience at NHS Lothian
As they can remain stable or progress slowly over years, patients with Myeloproliferative Neoplasms (MPNs), a blood cancer, need lifelong monitoring. As a result, their treatment can have a large impact on haematology services. In order to respond to the needs of its growing patient population, NHS Lothian established a JWP with Novartis Oncology to develop a new care pathway, adding an MPN Clinical Nurse Specialist (CNS) to the team. After the JWP period, a business case using data from the JWP resulted in this becoming a permanent position. Providing telephone and outpatient support to patients, the nurse-led service resulted in a 94% patient satisfaction rating, while freeing up 800 consultant appointments annually.
Case study: A new NET database in Sheffield
Neuroendocrine Tumours (NETs) are relatively rare and difficult to diagnose and treat, making accurate data on NETs extremely valuable. Sheffield Teaching Hospital Foundation NHS Trust worked with Novartis Oncology to devise a sophisticated database designed specifically to track data on patients with NETs. The new database has led to improved adherence to treatment guidelines, as well as allowing the Trust to make important contributions to our understanding of NETs. The Trust is now one of 10 European NET Society Centres of Excellence in the UK
ONC19-E006
January 2019